HONG KONG – Shanghai Green Valley (Group) Co. Ltd. is gearing up to file for approval in China later this year after its sodium oligomannurarate (GV-971) capsules significantly improved cognition among patients with mild to moderate Alzheimer's disease (AD) in phase III trials.